Microbiota-gut-brain axis and its affect inflammatory bowel disease:Pathophysiological concepts and insights for clinicians  

作　　者：Emanuele Sinagra Erika Utzeri Gaetano Cristian Morreale Carlo Fabbri Fabio Pace Andrea Anderloni 

机构地区：[1]Gastroenterology and Endoscopy Unit,Fondazione Istituto Giuseppe Giglio,Contrada Pietra Pollastra Pisciotto,Cefalù90015,Italy [2]Euro-Mediterranean Institute of Science and Technology,Palermo 90100,Italy [3]Nuova Casa di Cura di Decimomannu,Cagliari 09100,Italy [4]Section of Gastroenterology,S.Elia-Raimondi Hospital,Caltanissetta 93100,Italy [5]Gastroenterology and Digestive Endoscopy Unit,Forlì-Cesena,Azienda USL Romagna,Forlì47121,Italy [6]Unit of Gastroenterology,Bolognini Hospital,Bergamo 24100,Italy [7]Digestive Endoscopy Unit,Division of Gastroenterology,Humanitas Research Hospital,Rozzano 20089,Italy

出　　处：《World Journal of Clinical Cases》2020年第6期1013-1025,共13页世界临床病例杂志

摘　　要：Despite the bi-directional interaction between gut microbiota and the brain not being fully understood,there is increasing evidence arising from animal and human studies that show how this intricate relationship may facilitate inflammatory bowel disease(IBD)pathogenesis,with consequent important implications on the possibility to improve the clinical outcomes of the diseases themselves,by acting on the different components of this system,mainly by modifying the microbiota.With the emergence of precision medicine,strategies in which patients with IBD might be categorized other than for standard gut symptom complexes could offer the opportunity to tailor therapies to individual patients.The aim of this narrative review is to elaborate on the concept of the gutbrain-microbiota axis and its clinical significance regarding IBD on the basis of recent scientific literature,and finally to focus on pharmacological therapies that could allow us to favorably modify the function of this complex system.Despite the bi-directional interaction between gut microbiota and the brain not being fully understood,there is increasing evidence arising from animal and human studies that show how this intricate relationship may facilitate inflammatory bowel disease (IBD) pathogenesis,with consequent important implications on the possibility to improve the clinical outcomes of the diseases themselves,by acting on the different components of this system,mainly by modifying the microbiota.With the emergence of precision medicine,strategies in which patients with IBD might be categorized other than for standard gut symptom complexes could offer the opportunity to tailor therapies to individual patients.The aim of this narrative review is to elaborate on the concept of the gut brain-microbiota axis and its clinical significance regarding IBD on the basis of recent scientific literature,and finally to focus on pharmacological therapies that could allow us to favorably modify the function of this complex system.

关 键 词：IRRITABLE BOWEL syndrome Inflammatory BOWEL disease Gut-brain AXIS Therapy 

分 类 号：R574[医药卫生—消化系统]